Cargando…
Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders
Alveolar hypoxia is the most prominent feature of high altitude environment with well-known consequences for the cardio-pulmonary system, including development of pulmonary hypertension. Pulmonary hypertension due to an exaggerated hypoxic pulmonary vasoconstriction contributes to high altitude pulm...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916528/ https://www.ncbi.nlm.nih.gov/pubmed/33578749 http://dx.doi.org/10.3390/ijerph18041692 |
_version_ | 1783657497665470464 |
---|---|
author | Sydykov, Akylbek Mamazhakypov, Argen Maripov, Abdirashit Kosanovic, Djuro Weissmann, Norbert Ghofrani, Hossein Ardeschir Sarybaev, Akpay Sh. Schermuly, Ralph Theo |
author_facet | Sydykov, Akylbek Mamazhakypov, Argen Maripov, Abdirashit Kosanovic, Djuro Weissmann, Norbert Ghofrani, Hossein Ardeschir Sarybaev, Akpay Sh. Schermuly, Ralph Theo |
author_sort | Sydykov, Akylbek |
collection | PubMed |
description | Alveolar hypoxia is the most prominent feature of high altitude environment with well-known consequences for the cardio-pulmonary system, including development of pulmonary hypertension. Pulmonary hypertension due to an exaggerated hypoxic pulmonary vasoconstriction contributes to high altitude pulmonary edema (HAPE), a life-threatening disorder, occurring at high altitudes in non-acclimatized healthy individuals. Despite a strong physiologic rationale for using vasodilators for prevention and treatment of HAPE, no systematic studies of their efficacy have been conducted to date. Calcium-channel blockers are currently recommended for drug prophylaxis in high-risk individuals with a clear history of recurrent HAPE based on the extensive clinical experience with nifedipine in HAPE prevention in susceptible individuals. Chronic exposure to hypoxia induces pulmonary vascular remodeling and development of pulmonary hypertension, which places an increased pressure load on the right ventricle leading to right heart failure. Further, pulmonary hypertension along with excessive erythrocytosis may complicate chronic mountain sickness, another high altitude maladaptation disorder. Importantly, other causes than hypoxia may potentially underlie and/or contribute to pulmonary hypertension at high altitude, such as chronic heart and lung diseases, thrombotic or embolic diseases. Extensive clinical experience with drugs in patients with pulmonary arterial hypertension suggests their potential for treatment of high altitude pulmonary hypertension. Small studies have demonstrated their efficacy in reducing pulmonary artery pressure in high altitude residents. However, no drugs have been approved to date for the therapy of chronic high altitude pulmonary hypertension. This work provides a literature review on the role of pulmonary hypertension in the pathogenesis of acute and chronic high altitude maladaptation disorders and summarizes current knowledge regarding potential treatment options. |
format | Online Article Text |
id | pubmed-7916528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79165282021-03-01 Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders Sydykov, Akylbek Mamazhakypov, Argen Maripov, Abdirashit Kosanovic, Djuro Weissmann, Norbert Ghofrani, Hossein Ardeschir Sarybaev, Akpay Sh. Schermuly, Ralph Theo Int J Environ Res Public Health Review Alveolar hypoxia is the most prominent feature of high altitude environment with well-known consequences for the cardio-pulmonary system, including development of pulmonary hypertension. Pulmonary hypertension due to an exaggerated hypoxic pulmonary vasoconstriction contributes to high altitude pulmonary edema (HAPE), a life-threatening disorder, occurring at high altitudes in non-acclimatized healthy individuals. Despite a strong physiologic rationale for using vasodilators for prevention and treatment of HAPE, no systematic studies of their efficacy have been conducted to date. Calcium-channel blockers are currently recommended for drug prophylaxis in high-risk individuals with a clear history of recurrent HAPE based on the extensive clinical experience with nifedipine in HAPE prevention in susceptible individuals. Chronic exposure to hypoxia induces pulmonary vascular remodeling and development of pulmonary hypertension, which places an increased pressure load on the right ventricle leading to right heart failure. Further, pulmonary hypertension along with excessive erythrocytosis may complicate chronic mountain sickness, another high altitude maladaptation disorder. Importantly, other causes than hypoxia may potentially underlie and/or contribute to pulmonary hypertension at high altitude, such as chronic heart and lung diseases, thrombotic or embolic diseases. Extensive clinical experience with drugs in patients with pulmonary arterial hypertension suggests their potential for treatment of high altitude pulmonary hypertension. Small studies have demonstrated their efficacy in reducing pulmonary artery pressure in high altitude residents. However, no drugs have been approved to date for the therapy of chronic high altitude pulmonary hypertension. This work provides a literature review on the role of pulmonary hypertension in the pathogenesis of acute and chronic high altitude maladaptation disorders and summarizes current knowledge regarding potential treatment options. MDPI 2021-02-10 2021-02 /pmc/articles/PMC7916528/ /pubmed/33578749 http://dx.doi.org/10.3390/ijerph18041692 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sydykov, Akylbek Mamazhakypov, Argen Maripov, Abdirashit Kosanovic, Djuro Weissmann, Norbert Ghofrani, Hossein Ardeschir Sarybaev, Akpay Sh. Schermuly, Ralph Theo Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders |
title | Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders |
title_full | Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders |
title_fullStr | Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders |
title_full_unstemmed | Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders |
title_short | Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders |
title_sort | pulmonary hypertension in acute and chronic high altitude maladaptation disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916528/ https://www.ncbi.nlm.nih.gov/pubmed/33578749 http://dx.doi.org/10.3390/ijerph18041692 |
work_keys_str_mv | AT sydykovakylbek pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders AT mamazhakypovargen pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders AT maripovabdirashit pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders AT kosanovicdjuro pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders AT weissmannnorbert pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders AT ghofranihosseinardeschir pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders AT sarybaevakpaysh pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders AT schermulyralphtheo pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders |